Latest Opioid Stories
SAN ANTONIO, Feb. 4 /PRNewswire-USNewswire/ -- Research presented at the American Academy of Pain Medicine's 26th Annual Meeting provides early published data analyzing information gathered from California's prescription monitoring program, known as the Controlled Substances Utilization Review and Evaluation System (CURES). The analysis found a two-fold increase in the likelihood of individuals receiving opioids from multiple providers or "doctor shopping" when they were also being...
SAN ANTONIO, Feb. 4 /PRNewswire-USNewswire/ -- Doctors from the Mayo Clinic in Jacksonville, Florida showcased positive results of peripheral nerve stimulation (PNS) in a patient suffering from post-herpetic neuralgia (PHN), or pain after a herpes breakout. The case study was presented today at the American Academy of Pain Medicine's 26th Annual Meeting and adds to the growing body of knowledge about the potential for this non-opioid alternative to pain treatment. "Our case study is just...
SEATTLE, Jan. 28 /PRNewswire-FirstCall/ -- Omeros Corporation (Nasdaq: OMER) today announced that the National Institute on Drug Abuse (NIDA) is providing support for the Company's Addiction program. NIDA will fund substantially all of the costs of a Phase 2 clinical study to be conducted by New York State Psychiatric Institute researchers. In its Addiction program, Omeros is developing proprietary compositions that include peroxisome proliferator-activated receptor gamma (PPAR-gamma)...
A recent study, published in the January issue of Mayo Clinic Proceedings, demonstrates that in elderly patients undergoing hip fracture repair under spinal anesthesia with propofol sedation, the prevalence of delirium can be decreased by 50 percent with light sedation, compared to deep sedation."These data show that, for every 3.5 to 4.7 patients treated in this manner, one incident of delirium will be prevented," says Frederick Sieber, M.D., primary investigator of the study from...
NASHVILLE, Tenn., Jan. 5 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that data from clinical trials for Caldolor® (ibuprofen) Injection, an intravenous formulation of ibuprofen approved to treat pain and fever in adults, will be presented at a Breakfast Satellite Symposium on Tuesday, January 12, 2010 from 6:30 to 8:00 am ET. The symposium, entitled "New Advances in the Management of Pain and Fever in the Hospital Setting," will be held at the...
- Procedure Provides Efficient Mechanism to Pursue Approval in Multiple Jurisdictions - LAVAL, QC, Dec. 17 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced it has initiated the regulatory approval process for its twice-daily tramadol-acetaminophen formulation in Europe under the Decentralized Procedure (DCP). The DCP provides an efficient mechanism that allows a company to simultaneously pursue regulatory approval for a medicinal product in multiple...
NASHVILLE, Tenn. and GLEN ROCK, N.J., Dec. 15 /PRNewswire/ -- HealthLeaders-InterStudy and Fingertip Formulary find that 70 percent of surveyed pharmacy directors expect to cover Pfizer's tanezumab if it is approved for the treatment of chronic pain. Tanezumab, which is expected to be the first biologic approved for chronic pain and is administered intravenously under medical supervision, will likely be covered as a medical benefit rather than a pharmacy benefit according to surveyed...
Have you ever felt overly upset by a social snubbing? Your genetics, not your friends, may be at fault.Scientists have long known that opium-like painkillers, called opioids, relieve not only physical pain, but also some forms of emotional stress. Now, a new study reviewed by Faculty of 1000 Biology member Markus Heilig shows that small genetic differences in the gene for the opioid receptor can determine the intensity of people's responses to social rejection.In the study published in the...
NASHVILLE, Tenn., Dec. 3 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that data from a recent clinical trial for Caldolor® (ibuprofen) Injection, an intravenous treatment for pain and fever, will be presented at the 44th American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting in Las Vegas, Nevada, in December. The new data will be displayed in a poster presentation on Monday, December 7, from 2:30 to 5:00 pm PST (board...
PARSIPPANY, N.J., Dec. 1 /PRNewswire/ -- Pacira Pharmaceuticals, Inc., announced today that its second Phase III placebo controlled study of EXPAREL(TM) (DepoBupivacaine) met its primary endpoint. The multicenter, randomized, double-blind, parallel group, placebo controlled study in hemorrhoidectomy showed a statistically significant reduction in area under the curve analysis (AUC) of the NRS pain scores in patients receiving EXPAREL(TM) compared to placebo through 72 hours...
